Abstract:Objective The study assessed the clinical characteristics and response to acute intravenous antiarrhythmic drug therapy of supraventricular tachycardia (SVT) in children.Methods This was a multicenter prospective descriptive study including 257 children from First Hospital of Tsinghua University,Peking University First Hospital,Children's Hospital Affiliated to Capital Institute of Pediatrics and Beijing Anzhen Hospital who received intravenous antiarrhythmic drug therapy for SVT from July 2014 to February 2017.The clinical and tachycardia features,response to intravenous antiarrhythmic drug therapy of these children were characterized.Statistical analyses were performed using t test,Mann-Whitney U test,x2 test and H test.Results The onset of SVT occurred at any age with a distribution with positive skewness,57.6％ (n=148) children＜l year,17.5％ (n=45) childrenl ～＜3 years,10.5％ (n=27)children 3 ～＜6 years and 14.4％ (n=37) children ≥ 6 years of age.The percentages of SVT types were 49.4％ (n=127) for atrioventricular reentry tachycardia (AVRT),4.3％ (n=11) for atrioventricular nodal reentry tachycardia (AVNRT),26.8％ (n=69) for unclassified paroxysmal SVT and 19.5％ (n=50) for atrial tachycardia (AT),respectively.Tachycardia-induced cardionyopathy (TIC)secondary to SVT developed in 30 of 225 (13.3％).Left ventricular ejection fraction (LVEF) of the 27 children attacked by TIC returned to normal after successful control of SVT (41.1％-±6.3％ vs.60.3％±9.2％,t=-10.397,P=0.000).Complete termination of SVT by antiarrhythmic drugs was achieved in 164 of 257 (63.8％),partial termination rate was 18.7％ (48 of 257) and failure to terminate rate was 17.5％ (45 of 257).Propafenone (complete cardioversion in 98 (73.1％) of 134) and amiodarone (complete cardioversion in 23 (76.7％) of 30) showed better efficacy for SVT termination than adenosine (complete cardioversion in 26 (44.1％)59) (x2=20.524,P=0.000).Paroxysmal SVT had a higher termination rate on pharmacological therapy than AT (67.1％ vs.50.0％,x2=6.337,P=0.042).Patients of different age groups had significantly different response to antiarrhythmic therapy (x2=13.904,P=0.031).Children＜l year of age showed the least response to antiarrhythmic drug therapy with complete termination in 51 (55.4％)of 92.Adverse effects occurred in 9 patients (3.5％):Four patients had severe hypotensive shock using propafenone (n=3) and adenosine (n=1),and 3 patients had sinus arrest using adenosine.Conclusion Most (57.6％) children with SVT have their first clinical episode within 1 year of age,and AVRT is the most common type.TIC occurs in 13.3％ of children with SVT.Intravenous antiarrhythmic drug therapy has a 63.8％ complete termination rate for children with SVT and incidence of adverse effects is 3.5％.Propafenone and amiodarone are more effective for SVT termination in children than adenosine.Serious adverse effects may occur when using propafenone.

Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database

Central Serous Chorioretinopathy Secondary to Drugs: a Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Antipsychotics and Venous Thromboembolism Risk: A Meta-Analysis

A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system

Real-World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation.

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System

An analysis of clinical characteristics and acute treatment of supraventricular tachycardia in children from a multicenter study

Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase®

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective

Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)

The Role of Troponin testing in patients with Supraventricular Tachycardia, Systematic Review and Meta-Analysis

ADRs monitoring and analysis of cardiovascular drugs

A Global Pharmacovigilance Perspective

Anti-cancer Drugs Associated Atrial Fibrillation-An Analysis of Real-World Pharmacovigilance Data

Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database

Predictors of Polymorphic Ventricular Tachycardia and Ventricular Fibrillation in Patients with Takotsubo Syndrome